ArriVent BioPharma, Inc.
AVBPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ArriVent BioPharma, Inc. focuses on Biotechnology services and products. ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with. Valued at $1.41B, AVBP is a small-cap name in its sector. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Market Cap
$1.41B
Beta
1.52
P/E (TTM)
—
P/E (Fwd)
-8.71
EPS (TTM)
$-3.38
EPS (Fwd)
$-3.48
ROE
-55.2%
ROA
-34.7%
Cash
$326.4M
Total Debt
$419,000
Free CF
-$82.8M
52W Change
37.6%
Annual Financials
Cash vs Debt
ArriVent BioPharma, Inc. holds $326.4M in cash against $419K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$82.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -55.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
ArriVent BioPharma, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, AVBP has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ArriVent BioPharma, Inc.'s trajectory.